| Literature DB >> 32272678 |
Yun-A Kim1, Yoon Jeong Cho1, Sang Gyu Kwak2.
Abstract
The association of Helicobacter pylori (H. pylori) infection with functional dyspepsia has been well studied. However, the data on the relationship between H. pylori infection and irritable bowel syndrome (IBS) are conflicting. This study aims to elucidate the association between H. pylori infection and IBS. PubMed, Cochrane Library, CINAHL and SCOPUS databases were searched to identify eligible English articles published up to December 2019. Cross-sectional studies, case-control studies and cohort studies reporting both prevalence of H. pylori infection and IBS were selected for the detailed review. The pooled odds ratio (ORs) and their 95% confidence interval (CI) were calculated. A total of 7269 individuals in four cross-sectional studies and six case-control studies were included. The prevalence of H. pylori infection ranged from 12.8% to 73.4% in the control group, and 9.7% to 72.1% in the IBS group. The combined OR for H. pylori infection was 1.10 (95% CI: 0.93-1.29, I2: 37.5%). In a subgroup analysis of IBS defined according to Rome criteria, the OR for H. pylori infection was 1.10 (95% CI: 0.93-1.30, I2 = 31.7%). In this meta-analysis, H. pylori infection was not significantly associated with IBS. Well-designed studies are needed to identify the relationship between H. pylori infection and IBS.Entities:
Keywords: H. pylori; functional dyspepsia; irritable bowel syndrome
Year: 2020 PMID: 32272678 PMCID: PMC7177688 DOI: 10.3390/ijerph17072524
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow chart of the search strategy.
Characteristics of the studies included in meta-analysis.
| Author | Year | Country | Design | IBS Diagnostic Criteria | Sample Size (Total No. of Study Participants) | No. of IBS | No. of Control | No. of | No. of | Male (%) | Mean Age ± SD or Median Age (Range) | Quality Assessment (Newcastle-Ottawa Scale) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agreus L [ | 1995 | Sweden | Case-control | ELISA (Antibody-IgG for | Diagnostic criteria developed by authors | 150 | 50 | 50 | 16 | 23 | 36 | 48 (22–80) | S2, C0, E2 |
| Antonio M [ | 1999 | Spain | Case-control | Antibody-IgG for | Rome criteria | 100 | 50 | 50 | 27 | 29 | 50 | 34.1 ± 7.4 in IBS, 35.6 ± 5.6 in control | S2, C1, E2 |
| G. Richard Locke III [ | 2000 | USA | Cross-sectional | ELISA (Antibody-IgG for | Manning et al. | 148 | 35 | 77 | 9 | 11 | 42 | 31 (20–50) | S3, C2, O3 |
| Maura Corsetti [ | 2004 | Belgium | Cross-sectional | Endoscopic biopsy and stain | Rome Ⅱ | 309 | 144 | 165 | 14 | 21 | 33 | 42.0 ± 0.8 | S2, C0, O3 |
| Y. Zhao [ | 2010 | China | Cross-sectional | ELISA (Antibody-IgG for | Rome Ⅱ | 3148 | 147 | 3001 | 106 | 2204 | 47.8 | 42.5 ± 15.2 | S4, C2, O3 |
| J. Yakoob [ | 2012 | Pakistan | Case-control | Endoscopic biopsy | Rome Ⅲ | 330 | 170 | 160 | 91 | 71 | 69 in IBS, 66 in control | 40 ± 15 in IBS, 42 ± 14 in control | S2, C0, O3 |
| Su Youn Nam [ | 2013 | Korea | Cross-sectional | Endoscopic biopsy, UBT | Rome Ⅲ | 2769 | 258 | 2511 | 106 | 1224 | 65.5 in IBS, 60.3 in control | 45.3 ± 8.6 in IBS, 50.2 ± 9.9 in control | S3, C2, O3 |
| Al-Damarchi, A.T [ | 2018 | Iraq | Case-control | Rome Ⅳ | 135 | 60 | 75 | 21 | 23 | 22 in IBS, 42 in control | 33.5 ± 2.5 in IBS, 34.8 ± 3.1 in control | S2, C1, E1 | |
| Aziza I Salem [ | 2019 | Egypt | Case-control | Rome III | 120 | 40 | 40 | 10 | 12 | NA | 28 ± 9.5 in IBS, 33.5 ± 13.9 in control | S2, C2, E2 | |
| Odhar, H.A. [ | 2019 | Iraq | Case-control | Antibody-IgG for | Rome Ⅳ | 60 | 30 | 30 | 17 | 12 | 20 in IBS, 53.3 in control | 23 (19–50) in IBS, 23 (19–55) in control | S2, C1, E1 |
Abbreviations: SD, standard deviation; S, selection; C, comparability; E, exposure; O, outcome; NA, not available.
Figure 2Forest plot evaluating the combined odds ratio (OR) between irritable bowel syndrome (IBS) and Helicobacter pylori infection.
Figure 3Forest plot evaluating the combined OR between IBS and according to Rome criteria and H. pylori infection.
Figure 4Funnel plot of included articles.